IL1B and congenital rubella syndrome: In the treatment section below, an increasing number of studies have demonstrated the effectiveness of IL-1 receptor antagonists like anakinra and monoclonal antibodies like canakinumab against IL-1β in treating CRS and reducing CRS-related mortality.